Copyright
©The Author(s) 2021.
World J Gastrointest Endosc. Sep 16, 2021; 13(9): 391-406
Published online Sep 16, 2021. doi: 10.4253/wjge.v13.i9.391
Published online Sep 16, 2021. doi: 10.4253/wjge.v13.i9.391
Table 1 ICD-10-CM and PCS codes for diagnoses and procedures
Diagnosis | ICD-10-CM |
GI hemorrhage | Upper: I85.x1; (K25-K28).0,2,4,6; K29.x1; K318.11 K31.82 |
Lower: K50.x11; K51.x11; K55.21; K57.x1; K57.x3 | |
Total = upper + lower + K62.5; K92.0-2 | |
GI cancer | |
Esophageal cancer | C15; C49.A1; D00.1 |
Upper third | C15.3 |
Middle third | C15.4 |
Lower third | C15.5 |
Other/unspecified | C15.8-9; C49.A1; D00.1 |
Gastric cancer | C16; C49.A2; D00.2 |
Cardia | C16.0 |
Fundus | C16.1 |
Body | C16.2 |
Pyloric antrum | C16.3 |
Pylorus | C16.4 |
GIST | C49.A2 |
Other/unspecified | C16.5-9; D00.2 |
Small bowel cancer | C17; C49.A3; D01.49 |
Duodenum | C17.0 |
Jejunum | C17.1 |
Ileum | C17.2 |
GIST | C49.A3 |
Other/unspecified | C17.3-9; D01.49 |
Liver cancer | C22; D01.5 |
Hepatocellular carcinoma | C22.0 |
Other primary liver | C22.2-8; D01.5 |
Biliary cancer | C22.1; C24 |
Intrahepatic | C22.1 |
Extrahepatic | C24.0 |
Ampulla of Vater | C24.1 |
Other/unspecified | C24.8-9 |
Gallbladder cancer | C23 |
Pancreatic cancer | C25 |
Head | C25.0 |
Body | C25.1 |
Tail | C25.2 |
Duct | C25.3 |
Endocrine | C25.4 |
Other/unspecified | C25.7-9 |
Colorectal cancer | C18; C19; C20; C26.0; C49.A4-5; D01.0-4 |
Cecum | C18.0 |
Appendix | C18.1 |
Ascending colon | C18.2 |
Hepatic flexure | C18.3 |
Transverse colon | C18.4 |
Splenic flexure | C18.5 |
Descending colon | C18.6 |
Sigmoid | C18.7 |
Rectosigmoid junction | C19 |
Rectum | C20 |
Other/unspecified | C188.9-9; C26.0; C49.A4-5; D01.0-4 |
Acute kidney injury | N17; N19; N99.0; O90.4 |
Chronic kidney disease | D63.1; (E08-E13).22; I12.0,9; I13.10,11,20; N18; R88.0; Z49 |
Congestive heart failure | I50; I97.13x; O29.12x; Z95.812; I09.81; I11.0; I13.0,2 |
Cirrhosis and liver failure | K70.4; K70.3; K72; K91.82; K71.7; K74; K76.(6,7); K65.2; I85 |
Radiation gastroenteritis/proctitis | K52.0; K62.7 |
Metastasis | C77; C78; C79; C80.0 |
Chemotherapy and immunotherapy | Z92.21; Z51.11-12; T45.1X; K12.31; D61.81; D64.81 |
Severe malnutrition and cachexia | E40-43; R64 |
Obesity | E66.01; E66.09; E66.(1,2,8,9); Z68.3-4 |
Palliative care | Z521.5 |
Aspirin/antiplatelets | Z79.82; Z79.02 |
Anticoagulants | Z79.01 |
Intestinal infection | A00-09; A18.32; A21.3; A22.2; B37.82; B25.8-9 |
Hypovolemic shock | R57.1 |
Procedures | ICD-10-PCS |
Upper endoscopy | 06L34CZ; 0D5(1-9)8ZZ; 0DB(1-9)8ZX; 0DB(1-9)8ZZ; 0DBA8ZX; 0DJ08ZZ; 0DQ(6,7,9)8ZZ; 3E0G8TZ |
Colonoscopy | 06LY4CC; 0D5(E-Q)8ZZ; 0DB(B-Q)8ZZ; 0DB(B-Q)8ZX; 0DJD8ZZ |
Surgery | 0D(1,5,B,J,T); 0F(5,B,T); OW(J,3) excluding endoscopic approach |
Trans-arterial embolization | 04(L,V)(1,2,3,5,6,7,9,B)3DZ |
Radiation therapy | D(D,F,W)0(0-7)(0-6)Z(0,Z) |
Table 2 Comparison of gastrointestinal hemorrhage between inpatients who have and do not have gastrointestinal cancer
GI cancer | Total | ||||||
No | Yes | ||||||
Count | Within GI cancer (%) | Count | Within GI cancer (%) | Count | Within total (%) | ||
GI bleeding | No | 17242568 | 96.6 | 291115 | 90.5 | 17533683 | 96.5 |
Yes | 609695 | 3.4 | 30507 | 9.5 | 640202 | 3.5 | |
Total | 17852263 | 100 | 321622 | 100 | 18173885 | 100 |
Table 3 Tabulated representation of data of Figure 1 which shows to the prevalence of gastrointestinal hemorrhage according to the anatomic location of gastrointestinal cancer
Anatomic location of cancer | GI hemorrhage | ||||
No | Yes | ||||
n | Count | Row (%) | Count | Row (%) | |
Esophagus | 23674 | 21508 | 90.90 | 2166 | 9.10 |
Upper third | 773 | 725 | 93.80 | 48 | 6.20 |
Middle third | 1467 | 1349 | 92.00 | 118 | 8.00 |
Lower third | 6540 | 5843 | 89.30 | 697 | 10.70 |
Other/unspecified | 15161 | 13842 | 91.30 | 1319 | 8.70 |
Stomach | 27409 | 23103 | 84.30 | 4306 | 15.70 |
Cardia | 6829 | 5815 | 85.20 | 1014 | 14.80 |
Fundus | 471 | 351 | 74.50 | 120 | 25.50 |
Body | 1284 | 1004 | 78.20 | 280 | 21.80 |
Pyloric antrum | 1881 | 1561 | 83.00 | 320 | 17.00 |
Pylorus | 398 | 325 | 81.70 | 73 | 18.30 |
GIST | 2477 | 2060 | 83.20 | 417 | 16.80 |
Other/unspecified | 14410 | 12256 | 85.10 | 2154 | 14.90 |
Small bowel | 6469 | 5646 | 87.30 | 823 | 12.70 |
Duodenum | 3270 | 2760 | 84.40 | 510 | 15.60 |
Jejunum | 513 | 456 | 88.90 | 57 | 11.10 |
Ileum | 540 | 509 | 94.30 | 31 | 5.70 |
GIST | 872 | 737 | 84.50 | 135 | 15.50 |
Other/unspecified | 1322 | 1228 | 92.90 | 94 | 7.10 |
Liver | 33452 | 29111 | 87.00 | 4341 | 13.00 |
HCC | 27601 | 23877 | 86.50 | 3724 | 13.50 |
Other primary liver | 5988 | 5357 | 89.50 | 631 | 10.50 |
Bile ducts | 18706 | 17577 | 94.00 | 1129 | 6.00 |
Intrahepatic | 12515 | 11749 | 93.90 | 766 | 6.10 |
Extrahepatic | 2749 | 2608 | 94.90 | 141 | 5.10 |
Ampulla of Vater | 2143 | 2008 | 93.70 | 135 | 6.30 |
Other/unspecified | 1464 | 1368 | 93.40 | 96 | 6.60 |
Gallbladder | 4268 | 4049 | 94.90 | 219 | 5.10 |
Pancreas | 63636 | 59063 | 92.80 | 4573 | 7.20 |
Head | 17643 | 16469 | 93.30 | 1174 | 6.70 |
Body | 3077 | 2882 | 93.70 | 195 | 6.30 |
Tail | 3892 | 3630 | 93.30 | 262 | 6.70 |
Ducts | 774 | 718 | 92.80 | 56 | 7.20 |
Endocrine | 589 | 548 | 93.00 | 41 | 7.00 |
Other/unspecified | 38379 | 35489 | 92.50 | 2890 | 7.50 |
Colon and rectum | 148943 | 135410 | 90.90 | 13533 | 9.10 |
Cecum | 12171 | 10863 | 89.30 | 1308 | 10.70 |
Appendix | 3967 | 3835 | 96.70 | 132 | 3.30 |
Ascending | 16104 | 14458 | 89.80 | 1646 | 10.20 |
Hepatic flexure | 3280 | 2916 | 88.90 | 364 | 11.10 |
Transverse | 7439 | 6687 | 89.90 | 752 | 10.10 |
Splenic flexure | 2033 | 1851 | 91.00 | 182 | 9.00 |
Descending | 4239 | 3862 | 91.10 | 377 | 8.90 |
Sigmoid | 17602 | 15976 | 90.80 | 1626 | 9.20 |
Rectosigmoid | 17199 | 15527 | 90.30 | 1672 | 9.70 |
Rectum | 29634 | 26730 | 90.20 | 2904 | 9.80 |
Other/unspecified | 40531 | 37341 | 91.50 | 3190 | 8.50 |
Table 4 Bivariate analysis comparing various factors based on gastrointestinal hemorrhage status in a population of inpatients with gastrointestinal cancer
Inpatients with GI cancer | No GI hemorrhage | GI hemorrhage | P value | |||
n = 291115 | n = 30507 | |||||
Count/mean | Column%/SD | Count/mean | Column%/SD | |||
Demographic factors | ||||||
Age (yr) | 66.2 | ± 12.8 | 68.2 | ± 13.2 | < 0.001 | |
Female | 125898 | 43.30 | 11543 | 37.80 | < 0.001 | |
Race | White | 192544 | 68.30 | 18633 | 63.00 | < 0.001 |
Black | 37986 | 13.50 | 4727 | 16.00 | < 0.001 | |
Hispanic | 29010 | 10.30 | 3462 | 11.70 | < 0.001 | |
Asian or Pacific Islander | 11482 | 4.10 | 1562 | 5.30 | < 0.001 | |
Native American | 1494 | 0.50 | 189 | 0.60 | 0.015 | |
Other | 9345 | 3.30 | 999 | 3.40 | 0.543 | |
Socioeconomic factors | ||||||
Insurance | Medicare | 161272 | 55.50 | 18371 | 60.30 | < 0.001 |
Medicaid | 33523 | 11.50 | 3859 | 12.70 | < 0.001 | |
Private | 81599 | 28.10 | 6483 | 21.30 | < 0.001 | |
Self-pay | 6348 | 2.20 | 894 | 2.90 | < 0.001 | |
No charge | 628 | 0.20 | 71 | 0.20 | 0.544 | |
Other | 7379 | 2.50 | 799 | 2.60 | 0.373 | |
Median household income for patient ZIP Code | 1st quartile | 78840 | 27.60 | 8905 | 29.70 | < 0.001 |
2nd quartile | 73759 | 25.80 | 7733 | 25.80 | 0.965 | |
3rd quartile | 69806 | 24.40 | 7072 | 23.60 | 0.003 | |
4th quartile | 63693 | 22.30 | 6241 | 20.80 | < 0.001 | |
Comorbidities | ||||||
Acute kidney injury | 55007 | 18.90 | 7849 | 25.70 | < 0.001 | |
Chronic kidney disease | 38425 | 13.20 | 5766 | 18.90 | < 0.001 | |
Heart failure | 8704 | 3.00 | 1289 | 4.20 | < 0.001 | |
Cirrhosis and liver failure | 32194 | 11.10 | 6154 | 20.20 | < 0.001 | |
Intestinal infection | 6694 | 2.30 | 753 | 2.50 | 0.06 | |
Cancer related | ||||||
Metastasis | 125345 | 43.10 | 12120 | 39.70 | < 0.001 | |
Chemo and Immunotherapy | 57005 | 19.60 | 4314 | 14.10 | < 0.001 | |
Radiation gastroenteritis/proctitis | 849 | 0.30 | 189 | 0.60 | < 0.001 | |
Palliative care | 38129 | 13.10 | 5318 | 17.40 | < 0.001 | |
Nutritional status | ||||||
Severe malnutrition and cachexia | 41008 | 14.10 | 4952 | 16.20 | < 0.001 | |
Obesity | 32691 | 11.20 | 3127 | 10.30 | < 0.001 | |
Use of antithrombotic/anticoagulants | ||||||
Aspirin/antiplatelets | 30778 | 10.60 | 3605 | 11.80 | < 0.001 | |
Anticoagulants | 22753 | 7.80 | 3345 | 11.00 | < 0.001 |
Table 5 The results of multivariate analysis showing the predictors of gastrointestinal hemorrhage in a population of patients with gastrointestinal cancer
Predictors of GI hemorrhage | ||||
aOR | 95%CI | P value | ||
Demographic factors | ||||
Age (yr) | 1.01 | (1.01-1.02) | < 0.001 | |
Female | 0.84 | (0.81-0.86) | < 0.001 | |
Race | White- Reference | 1.00 | - | - |
Black | 1.27 | (1.22-1.31) | < 0.001 | |
Hispanic | 1.19 | (1.14-1.24) | < 0.001 | |
Asian or Pacific Islander | 1.42 | (1.34-1.50) | < 0.001 | |
Native American | 1.24 | (1.06-1.46) | 0.007 | |
Other | 1.13 | (1.05-1.21) | 0.001 | |
Socioeconomic factors | ||||
Insurance | Medicare- Reference | 1.00 | - | - |
Medicaid | 1.17 | (1.12-1.22) | < 0.001 | |
Private | 0.91 | (0.88-0.94) | < 0.001 | |
Self-pay | 1.44 | (1.34-1.56) | < 0.001 | |
No charge | 1.21 | (0.94-1.56) | 0.148 | |
Other | 1.03 | (0.95-1.12) | 0.468 | |
Median household income for patient ZIP Code | 1st quartile- Reference | 1.00 | - | - |
2nd quartile | 0.98 | (0.95-1.01) | 0.246 | |
3rd quartile | 0.96 | (0.93-0.99) | 0.022 | |
4th quartile | 0.94 | (0.90-0.97) | < 0.001 | |
Comorbidities | ||||
Acute kidney injury | 1.17 | (1.13-1.20) | < 0.001 | |
Chronic kidney disease | 1.22 | (1.18-1.26) | < 0.001 | |
Heart failure | 1.19 | (1.12-1.27) | < 0.001 | |
Cirrhosis and liver failure | 1.84 | (1.78-1.90) | < 0.001 | |
Cancer related | ||||
Metastasis | 0.93 | (0.90-0.95) | < 0.001 | |
Chemo and Immunotherapy | 0.74 | (0.72-0.77) | < 0.001 | |
Radiation gastroenteritis/proctitis | 2.39 | (2.02-2.81) | < 0.001 | |
Palliative care | 1.21 | (1.17-1.26) | < 0.001 | |
Nutritional status | ||||
Severe malnutrition and cachexia | 1.12 | (1.08-1.15) | < 0.001 | |
Obesity | 0.94 | (0.90-0.98) | 0.001 | |
Use of antithrombotic/anticoagulants | ||||
Aspirin/antiplatelets | 1.09 | (1.05-1.13) | < 0.001 | |
Anticoagulants | 1.48 | (1.42-1.54) | < 0.001 |
Table 6 The results of multivariate analysis showing the odds ratio of inpatient mortality associated with different interventions (endoscopy, surgery, embolization, radiation)
GI bleeding patients with cancer | ||||||||||
All GI Ca | Esophageal Ca | Gastric Ca | Hepatic Ca | Biliary Ca | Gallbladder Ca | Pancreatic Ca | Small bowel Ca | Colorectal Ca | ||
Mortality aOR (95%CI) | Endoscopy | 0.42 (0.38-0.46) | 0.42 (0.31-0.57) | 0.42 (0.32-0.54) | 0.36 (0.29-0.43) | 0.43 (0.28-0.66) | 0.71 (0.24-2.11) | 0.36 (0.29-0.44) | 1.19 (0.59-2.43) | 0.45 (0.38-0.54) |
Surgery | 0.97 (0.84-1.13) | - | 1.73 (1.00-3.00) | 1.30 (0.67-2.53) | - | - | 0.85 (0.49-1.48) | 2.26 (0.95-5.36) | 1.33 (1.09-1.62) | |
Trans-arterial embolization | 1.35 (1.02-1.80) | - | 1.46 (0.81-2.62) | 1.12 (0.55-2.30) | - | - | 0.98 (0.56-1.69) | - | 2.52 (1.23-5.15) | |
Radiation therapy | 0.55 (0.29-1.05) | - | - | - | - | - | - | - | - |
- Citation: Minhem MA, Nakshabandi A, Mirza R, Alsamman MA, Mattar MC. Gastrointestinal hemorrhage in the setting of gastrointestinal cancer: Anatomical prevalence, predictors, and interventions. World J Gastrointest Endosc 2021; 13(9): 391-406
- URL: https://www.wjgnet.com/1948-5190/full/v13/i9/391.htm
- DOI: https://dx.doi.org/10.4253/wjge.v13.i9.391